Psychiatric evaluation often begins with patients facing a daunting challenge: articulating deeply personal and sometimes uncomfortable experiences within a limited consultation window. The initial psychiatric interview is crucial, setting the stage for diagnosis and treatment. However, patients’ reticence and the time constraints medical professionals face can impair the thorough collection of clinical information. KAIST researchers, in collaboration with experts at Gangnam Severance Hospital, recognized these barriers and sought to create a large language model (LLM)-based system that allows patients to first engage with an AI interlocutor before meeting their psychiatrist, thereby helping them organize and clarify their thoughts beforehand.

The architecture underlying this system exemplifies cutting-edge developments in conversational AI, blending advanced natural language understanding with domain-specific psychiatric knowledge. Unlike generic chatbots, this AI actively adapts the flow of conversation based on real-time patient responses. It analyzes patient input, cross-referencing it with specialized psychiatric frameworks to identify critical clinical indicators and dynamically generates subsequent questions. This ensures the interview remains highly pertinent, leading patients through a structured, supportive dialogue that mirrors the expertise of a trained clinician.

Beyond simple inquiry, the AI incorporates sophisticated counseling strategies historically reserved for human professionals. It offers empathetic expressions, summarizes patient statements to confirm understanding, and seeks to clarify ambiguous remarks tactfully. Such features are designed not just to extract information but to build rapport with patients, reducing their anxiety and encouraging openness. This emotional resonance within AI-driven dialogue stands as a landmark achievement in human-computer interaction, especially relevant in psychiatric contexts where empathy significantly influences therapeutic outcomes.

The efficacy of this technology was rigorously evaluated through simulations involving 1,440 virtual patients, enabling the team to benchmark its performance comprehensively. Results demonstrated that the AI-based system could reliably gather key clinical data required for accurate diagnosis in the vast majority of cases, and crucially, this occurs within approximately 30 minutes—an efficient timeframe that respects both patient endurance and clinical workload. This ability to streamline the initial assessment suggests practical scalability in real healthcare environments.

Following the interview, the system synthesizes the conversational data into a detailed clinical dashboard. This visualization tool highlights symptoms, potential diagnoses, and other salient information, granting psychiatrists a comprehensive overview before meeting the patient. By preloading clinicians with this structured insight, the AI frees them to concentrate their in-person sessions on nuanced counseling and treatment planning, arguably enhancing the quality of patient care and optimizing consultation efficiency.

Importantly, the KAIST team emphasizes that this AI system is conceived not as a replacement for human psychiatrists but as a “coachable apprentice” that undertakes routine, structured information gathering. The final diagnostic reasoning and therapeutic decisions remain firmly within the domain of trained medical professionals. This collaborative model leverages the complementary strengths of AI—processing vast amounts of data rapidly and systematically—with the irreplaceable human capacities for empathy, ethical judgment, and clinical experience.

Nevertheless, the research acknowledges current limitations. The AI can struggle to interpret the subtleties of emotional expression and may not be fully equipped to handle sensitive or crisis situations autonomously. Accordingly, human oversight is indispensable to ensure patient safety and uphold the standards of psychiatric care. This clear demarcation of roles delineates ethical boundaries and underscores the complementary nature of AI assistance within mental health trajectories.

Professor Uichin Lee, leading the digital innovation at KAIST, underscored the broader implications of this development: by reducing the burden associated with initial history-taking, clinicians can allocate more time and attention to deeper therapeutic engagement during subsequent consultations. This paradigm shift illustrates a vision for future healthcare where human expertise and AI capabilities synergistically enhance each other’s effectiveness.

This groundbreaking work was first presented at the ACM Conference on Human Factors in Computing Systems (CHI) 2026, a premier venue showcasing advances in human-computer interaction. The lead author, doctoral candidate Yugyeong Jung, alongside a multidisciplinary team spanning computer science, industrial design, and psychiatry, meticulously combined technical sophistication with clinical insights to realize this AI tool.

Supported by the Digital Columbus Project under the Institute of Information & Communications Technology Planning & Evaluation, the research represents a significant investment in digital health innovation. It signals a promising conduit through which AI can be responsibly integrated into complex medical settings—ushering in novel models that balance technological prowess with human-centric care.

As mental health challenges escalate globally, such AI-assisted tools present an exciting frontier. They hold the promise not only of alleviating systemic pressures on overstretched psychiatric services but also of fostering patient empowerment through more approachable and personalized preliminary assessments. Ultimately, this fusion of AI and psychiatry could redefine pathways to mental wellness, embedding technology as a trusted collaborator rather than a mere adjunct.

Subject of Research: Not applicable

Article Title: Toward Flexible Psychiatric History-Taking and Visualization: Exploring Clinician Perspectives with Large Language Models

News Publication Date: 24 May 2026

Web References: http://dx.doi.org/10.1145/3772318.3790970

Image Credits: KAIST

Keywords: Health care, Artificial Intelligence, Large Language Models, Psychiatric Interview, Mental Health, Human-Computer Interaction, Digital Health, Clinical Decision Support

The study analyzed heart sounds from approximately 1,800 patients, employing an advanced AI algorithm specifically designed to recognize subtle patterns associated with valvular heart disease. Traditional methods for diagnosing these conditions hinge heavily on echocardiography, which, while effective, poses challenges due to its cost, time consumption, and availability within healthcare systems. The research showcases how integrating AI into existing diagnostic processes may not only enhance the accuracy of diagnoses but also mitigate the overwhelming pressures faced by healthcare providers, particularly under the strain of an ageing population.

One of the standout findings of this research is the AI’s impressive accuracy rate in diagnosing severe aortic stenosis at 98%. This form of valve disease is the most prevalent requiring surgical intervention and often goes unnoticed until it reaches advanced stages, resulting in dire consequences for the patient. Similarly, the AI correctly identified 94% of cases involving severe mitral regurgitation where the heart valve fails to close entirely, leading blood to flow backward, thereby complicating the heart’s function.

In contrast to general practitioners who may utilize traditional stethoscopes during patient evaluations, the AI system proved to be a superior tool. The researchers highlighted that, in a head-to-head comparison, the algorithm outperformed every single GP involved in the study, who varied widely in their evaluation methodologies. This disparity underscores a crucial gap in existing healthcare practices, where human error may often lead to undetected cases of valve disease.

The research team emphasized that valvular heart disease represents a silent epidemic within the population. Professor Anurag Agarwal, who led the study, pointed out alarming statistics indicating that around 300,000 individuals in the UK are living with severe aortic stenosis, with a significant proportion unaware of their condition. As symptoms can often emerge only when the disease has progressed considerably, early detection is paramount to ensuring patients receive timely treatment, which can be life-saving.

The AI system used in this study capitalizes on a methodology that deviates from conventional diagnostic techniques. Instead of training the algorithm solely to detect audible heart murmurs—typically associated with valve diseases—the researchers trained it on echocardiographic data. This approach allowed the AI to discern nuanced acoustic patterns that might elude human detection, thereby identifying cases without prominent murmurs and enhancing the likelihood of successful early diagnosis.

Moreover, the technology shows promise as a rapid screening tool that could be integrated into primary care settings. In an era where timely diagnostics can drastically affect patient outcomes, the ability to conduct quick assessments with minimal training required for healthcare staff opens new doors for accessible healthcare services. If healthcare providers can efficiently rule out significant disease cases through such AI-driven tools, it will free up vital resources, allowing clinicians to focus on individuals in dire need of further evaluation or intervention.

This innovative approach could revolutionize the landscape of cardiovascular diagnostics. Traditionally, diagnosing valve diseases necessitates lengthy delays associated with echocardiograms due to high demand within healthcare services, particularly in the NHS. Given these constraints, an AI solution could serve as a first line of defense, enabling screenings to occur sooner and encouraging nascent patients to seek necessary care before life-altering complications arise.

While the study laid a robust foundation by validating AI’s efficacy against GP evaluations, the researchers stress that further trials are necessary to refine the technology further. These additional trials must be conducted within real-world scenarios involving diverse patient populations to assess the algorithm’s adaptability across different demographics and healthcare settings. Furthermore, the researchers acknowledge the challenge of accurately detecting moderate forms of valve disease, which are inherently more complex and less clearly delineated than their severe counterparts.

The implications of such advancements in heart disease diagnostics echo beyond individual patient outcomes. As global demographics shift, leading to an increasingly aged population, healthcare systems will inevitably face rising challenges. The implementation of AI-assisted diagnostic screenings could alleviate some of these pressures, offering a sustainable solution that marries technology with human expertise.

Addressing the often-ignored reality of cardiovascular health, the research emphasizes the need for proactive measures and innovative solutions to combat the impending surge of heart disease diagnoses expected in the coming years. As researchers like Professors Agarwal and Steeds illuminate, the treatment landscape for valve disease is evolving, and harnessing AI’s full potential could lead to more patients receiving corrective treatments like valve repair or replacement before irrevocable damage occurs.

In a climate where technological advancements continue to reshape the fabric of healthcare, this study stands as a testament to the promise of AI in revolutionizing patient care. As academia, industry, and healthcare intertwine, initiatives like these will become the cornerstone of preventative care models, fostering healthier populations and longer, more fulfilling lives.

With the research entering the dialogue around healthcare innovation, it provides hope for a future where early detection of heart disease becomes not just ideal but standard practice. The promise of AI could indeed reshape the paradigm, enabling healthcare systems to respond proactively, ensuring that no patient remains in the dark about potentially life-threatening conditions until it is too late.

As this collaborative research involving engineers, cardiologists, and nursing staff pushes the boundaries of existing medical knowledge, the potential applications of such technology are vast. It invites both excitement and urgency as the healthcare community begins to embrace AI as a partner in patient care, rather than a mere tool in mechanical processes. The road to universal adoption may be long and complex, but with continued dedication to research and development, the dream of safer, more timely treatments for heart valve diseases could soon move closer to reality.

In conclusion, the intersection of artificial intelligence and cardiovascular diagnostics represents a significant leap forward in modern medicine. As the study suggests, the potential to save thousands of lives by revolutionizing the screening process is not out of reach. Continuous efforts to refine this technology and validate its application within healthcare settings hold the promise that patients might benefit from timely interventions, ultimately improving the prognosis and quality of life for those affected by valvular heart disease.

Subject of Research: People
Article Title: Development and Validation of AI-Enhanced Auscultation for Valvular Heart Disease Screening through a Multi-Centre Study
News Publication Date: 10-Feb-2026
Web References: http://dx.doi.org/10.1038/s44325-026-00103-y
References: None
Image Credits: None

Keywords

Artificial intelligence, heart disease, valve disease, early detection, healthcare innovation, diagnostic algorithms, cardiac health, patient screening, echocardiography, AI diagnostics, preventive medicine, cardiology.

Cardiovascular disease (CVD) stands as a leading cause of death worldwide, yet its risk factors tend to be under-recognized and poorly managed among women. Traditional cardiovascular risk prediction models often underperform in females, primarily due to biological differences and gaps in representation during their development. Moreover, modern risk calculators, though improved, generally rely on extensive clinical data, including detailed medical histories and lab results, which are not always available or accessible. This leaves a critical need for simpler, equally reliable predictive tools.

The link between breast arterial calcification (BAC)—a visible marker on mammograms—and CVD risk has intrigued researchers for years. However, BAC alone has proven an inconsistent predictor, partly because it is independent of some common risk factors such as obesity and even negatively correlated with smoking, limiting its standalone utility. Seeking a more comprehensive understanding, researchers hypothesized that analyzing the broader internal composition and tissue characteristics within mammograms might yield a richer, more nuanced source of cardiovascular risk information.

To test this hypothesis, the team analyzed data from 49,196 women enrolled in the Lifepool cohort registry in Victoria, Australia, between 2009 and 2020. The cohort had an average age of 59 and was followed for nearly nine years on average. These women provided essential health background data, including age, smoking status, alcohol intake, body mass index (BMI), diabetes history, and medication use for high blood pressure, cholesterol, and blood thinning. Additional contextual factors such as menopause status, reproductive history, hormone therapy, and breast interventions (e.g., surgery or radiation) were also recorded to refine the analysis.

Over the follow-up period, 3,392 of these women experienced a first major cardiovascular event, including coronary artery disease, myocardial infarction, stroke, or heart failure. This significant event rate highlighted the imperative for more effective risk stratification methods in this population. The researchers developed a convolutional neural network, a form of deep learning, trained to extract and interpret complex patterns and features within mammographic images alongside the woman’s age to forecast the likelihood of a cardiovascular event within ten years.

Remarkably, the AI model’s predictive performance rivaled that of contemporary risk assessment tools such as New Zealand’s ‘PREDICT’ algorithm and the American Heart Association’s ‘PREVENT’ calculator, which both incorporate multifaceted clinical factors. Adding traditional clinical risk factors to the AI model slightly enhanced its accuracy, indicating that standard risk data may still have supplementary value. However, the AI’s ability to function effectively using only mammographic images and age underscores its potential as a standalone screening modality.

Several technical challenges and limitations were acknowledged by the researchers. Variability in image quality and characteristics due to different mammography scanners could affect the generalizability of the model across clinical settings. Furthermore, the comparative cardiovascular risk factors were self-reported, potentially introducing biases. The AI model’s performance inherently depends on the diversity and scope of its training data, raising questions about external validity in diverse populations beyond the Australian cohort.

Despite these caveats, the study’s most compelling advantage is its utilization of an already established screening infrastructure—routine mammography—which millions of women undergo worldwide. This ‘two-for-one’ screening concept offers significant efficiencies for both women and healthcare systems by capturing cardiovascular risk information without additional tests, medical visits, or data collection. Moreover, it presents a unique opportunity to elevate cardiovascular disease awareness among women, who historically perceive heart disease as a lesser threat compared to breast cancer.

In an editorial accompanying the study, experts from the University of Sydney emphasize the critical gap in cardiovascular risk recognition among women. They note that cardiovascular disease accounts for approximately 90% of deaths compared with breast cancer globally, a stark statistic that defies common public perceptions. They further suggest that mammography appointments could serve as vital ‘touchpoints’ to inform women about their heart health risks and potentially catalyze earlier interventions.

The embrace of machine learning for cardiovascular risk assessment is part of a growing trend in medical diagnostics and prognostics. However, translating these promising computational tools from research settings into routine clinical practice remains a significant hurdle. Implementation barriers include integrating AI algorithms with existing medical record systems, ensuring model transparency and interpretability, addressing ethical considerations, and securing regulatory approvals and clinician acceptance.

Ultimately, this study marks a pivotal step towards personalized cardiovascular risk screening tailored specifically for women, harnessing accessible imaging data in innovative ways. Ongoing refinement, broader validation in diverse populations, and concerted efforts to overcome implementation challenges will be essential to fully realize the potential of mammography-based machine learning for cardiovascular risk prediction. The convergence of medical imaging, AI, and preventive cardiology foreshadows a future where women’s heart health can be addressed proactively and efficiently within the framework of routine breast cancer screening programs.

Subject of Research: People
Article Title: Predicting cardiovascular events from routine mammograms using machine learning
News Publication Date: 16-Sep-2025
Web References: http://dx.doi.org/10.1136/heartjnl-2025-325705
Keywords: Cardiovascular disease, Mammography